Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCORI Approves 45 CER Projects

This article was originally published in The Pink Sheet Daily

Executive Summary

The Patient-Centered Outcomes Research Institute awarded 45 grants for comparative effectiveness research in its Dec. 17 announcement, which included the first drug vs. drug clinical trial for neuropathy and studies of medication adherence.

You may also be interested in...



PCORI’s Selby Expects More Drug-Related Comparative Research In 2014

Research involving drugs has been limited since the Patient-Centered Outcomes Research Institute began project funding, but institute Executive Director Joe Selby expects that to change as PCORI prepares to issue funding announcements for pragmatic trials.

Medication Adherence: A Positive Story You Are Not Hearing

Pharmaceutical companies are spending more to help patients adhere to their therapeutic regimens – an almost universally recognized way to improve health outcomes and pharma’s bottom line. But an unclear legal and regulatory climate and poor understanding of the adherence problems it is trying to solve means industry isn’t trumpeting what could be one of its best health care value arguments.

A Personal Touch Can Help Medication Adherence, Mass General Finds

As themes of patient-centered outcomes and personalized medicine become more common in drug development, the concepts also are playing out in the medication adherence space, as shown in a program at Massachusetts General Hospital.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS075184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel